Health Trials

Clinical trials

4

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

To Evaluate the Efficacy and Safety of SG301 SC Injection in Systemic Lupus Erythematosus

This was a multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical study. The primary objective was to evaluate the efficacy of SG301 SC injection in participants with Systemic Lupus Erythematosus (SLE) based on the Systemic Lupus Erythematosus Responder Index -4 (SRI-4) response rate. The secondary objectives were to assess the safety, pharmacokinetics, pharmacodynamics, and immunogenicity profiles of SG301 SC injection in these participants .

Participants needed: 120
Trial details
Phase: Phase 2Age: 18-70Biological sex: AllType: InterventionalSponsor: Hangzhou Sumgen Biotech Co., Ltd.Updated: Apr 2, 2026Locations: 1
Eligibility criteria

Voluntarily participate in the clinical study and sign a written informed consen... [+6]

Previous use of CD38 or monoclonal antibodies targeting CD38. [+14]

Read more
Status: Not yet recruiting

To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma

The primary objective of this study was to evaluate the safety and tolerability of SG2918 in patients with relapsed/refractory multiple myeloma.

Participants needed: 40
Trial details
Phase: Phase 1, Phase 2Age: 18-80Biological sex: AllType: InterventionalSponsor: Hangzhou Sumgen Biotech Co., Ltd.Updated: Mar 6, 2026Locations: 4
Eligibility criteria

Age ≥ 18 years and ≤ 80 years. [+8]

Patients with primary refractory multiple myeloma. [+26]

Read more
Status: Recruiting

A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients

The purpose of this study is to evaluate the effects of the addition of SG301 injection to pomalidomide and dexamethasone in subjects with relapsed or refractory multiple myeloma.

Participants needed: 360
Trial details
Phase: Phase 3Age: 18-75Biological sex: AllType: InterventionalSponsor: Hangzhou Sumgen Biotech Co., Ltd.Updated: Jun 27, 2025Locations: 12
Eligibility criteria

Understand and voluntarily sign the informed consent form (ICF). [+8]

Primary refractory multiple myeloma defined as participants who had never achiev... [+13]

Read more
Status: Recruiting

SG1906 for CLDN18.2-Positive Solid Tumors

This is a Phase Ia/Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SG1906 in Patients with CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Solid Tumors.

Participants needed: 60
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Hangzhou Sumgen Biotech Co., Ltd.Updated: Jun 25, 2025Locations: 9
Eligibility criteria

Understand and voluntarily sign the informed consent form (ICF). [+18]

Presence of active central nervous system metastatic lesions; presence of metast... [+29]

Read more